$3.10
7.64% day before yesterday
NYSE, Sep 20, 10:20 pm CET
ISIN
US03237H1014
Symbol
AMLX
Sector
Industry

Amylyx Pharmaceuticals Stock price

$3.10
+0.84 37.17% 1M
+0.13 4.38% 6M
-11.62 78.94% YTD
-15.47 83.30% 1Y
-14.97 82.84% 3Y
-14.97 82.84% 5Y
-14.97 82.84% 10Y
NYSE, Closing price Fri, Sep 20 2024
+0.22 7.64%
ISIN
US03237H1014
Symbol
AMLX
Sector
Industry

Key metrics

Market capitalization $211.06m
Enterprise Value $-95.61m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 1.61
EV/Sales (TTM) EV/Sales -0.32
P/S ratio (TTM) P/S ratio 0.71
P/B ratio (TTM) P/B ratio 0.81
Revenue growth (TTM) Revenue growth 55.71%
Revenue (TTM) Revenue $298.76m
EBIT (operating result TTM) EBIT $-154.91m
Free Cash Flow (TTM) Free Cash Flow $-59.56m
Cash position $309.81m
EPS (TTM) EPS $-2.45
P/E forward negative
P/S forward 2.41
EV/Sales forward negative
Short interest 2.40%
Show more

Is Amylyx Pharmaceuticals a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.

Amylyx Pharmaceuticals Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Amylyx Pharmaceuticals forecast:

1x Buy
14%
6x Hold
86%

Analyst Opinions

7 Analysts have issued a Amylyx Pharmaceuticals forecast:

Buy
14%
Hold
86%

Financial data from Amylyx Pharmaceuticals

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
299 299
56% 56%
100%
- Direct Costs 140 140
850% 850%
47%
159 159
10% 10%
53%
- Selling and Administrative Expenses 179 179
14% 14%
60%
- Research and Development Expense 134 134
33% 33%
45%
-154 -154
92% 92%
-51%
- Depreciation and Amortization 1.13 1.13
36% 36%
0%
EBIT (Operating Income) EBIT -155 -155
91% 91%
-52%
Net Profit -166 -166
128% 128%
-56%

In millions USD.

Don't miss a Thing! We will send you all news about Amylyx Pharmaceuticals directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Amylyx Pharmaceuticals Stock News

Neutral
GlobeNewsWire
6 days ago
NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) breached their fiduciary duties to shareholders.
Neutral
Business Wire
25 days ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that management will participate in the following upcoming investor conferences, which are being conducted in-person in New York City: Morgan Stanley 22nd Annual Global Healthcare Conference: Fireside chat on Thursday, September 5, 2024, at 1:50pm ET Baird 2024 Gl...
Neutral
Seeking Alpha
about one month ago
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX ) Q2 2024 Earnings Call Transcript August 8, 2024 8:00 AM ET Company Participants Lindsey Allen - Head of Investor Relations and Communications Justin Klee - Co-Chief Executive Officer Joshua Cohen - Co-Chief Executive Officer Camille Bedrosian - Chief Medical Officer James Frates - Chief Financial Officer Conference Call Participants Charlie Yang - Ban...
More Amylyx Pharmaceuticals News

Company Profile

Amylyx Pharmaceuticals, Inc. operates as a biopharmaceutical company, which engages in the provision of disease-modifying solutions for neurodegenerative diseases. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.

Head office United States
CEO Josh Klee
Employees 384
Founded 2013
Website www.amylyx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today